PBPlacido Bramanti

Placido Bramanti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Placido Bramanti has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adrenomedullin in inflammatory process associated with experimental pulmonary fibrosis

    by Rosanna Di Paola, Elena Talero, Maria Galuppo, Emanuela Mazzon, Placido Bramanti, Virginia Motilva, Salvatore Cuzzocrea

    Background: Adrenomedullin (AM), a 52-amino acid ringed-structure peptide with C-terminal amidation, was originally isolated from human pheochromocytoma. AM are widely distributed in various tissues and acts as a local vasoactive hormone in various conditions. Methods: In the present study, we investigated the efficacy of AM on the animal model of bleomycin (BLM)-induced lung injury. Mice were subjected to intratracheal administration of BLM and were assigned to receive AM daily by an intraperitoneal injection of 200 ngr/kg. Results and Discussion: Myeloperoxidase activity, lung histology, immunohistochemical analyses for cytokines and adhesion molecules expression, inducible nitric oxide synthase (iNOS), nitrotyrosine, and poly (ADP-ribose) polymerase (PARP) were performed one week after fibrosis induction. Lung histology and transforming growth factor beta (TGF-β) were performed 14 and 21 days after treatments. After bleomycin administration, AM-treated mice exhibited a reduced degree of lung damage and inflammation compared with BLM-treated mice, as shown by the reduction of (1) myeloperoxidase activity (MPO), (2) cytokines and adhesion molecules expression, (3) nitric oxide synthase expression, (4) the nitration of tyrosine residues, (5) poly (ADP-ribose) (PAR) formation, a product of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) (6) transforming growth factor beta (TGF-β) (7)and the degree of lung injury. Conclusions: Our results indicate that AM administration is able to prevent bleomycin induced lung injury through the down regulation of proinflammatory factors.


  • Open Access

    Selective adenosine A2Areceptor agonists and antagonists protect against spinal cord injury through peripheral and central effects

    by Irene Paterniti, Alessia Melani, Sara Cipriani, Francesca Corti, Tommaso Mello, Emanuela Mazzon, Emanuela Esposito, Placido Bramanti, Salvatore Cuzzocrea, Felicita Pedata

    Background: Permanent functional deficits following spinal cord injury (SCI) arise both from mechanical injury and from secondary tissue reactions involving inflammation. Enhanced release of adenosine and glutamate soon after SCI represents a component in the sequelae that may be responsible for resulting functional deficits. The role of adenosine A2Areceptor in central ischemia/trauma is still to be elucidated. In our previous studies we have demonstrated that the adenosine A2Areceptor-selective agonist CGS21680, systemically administered after SCI, protects from tissue damage, locomotor dysfunction and different inflammatory readouts. In this work we studied the effect of the adenosine A2Areceptor antagonist SCH58261, systemically administered after SCI, on the same parameters. We investigated the hypothesis that the main action mechanism of agonists and antagonists is at peripheral or central sites.Methods: Spinal trauma was induced by extradural compression of SC exposed via a four-level T5-T8 laminectomy in mouse. Three drug-dosing protocols were utilized: a short-term systemic administration by intraperitoneal injection, a chronic administration via osmotic minipump, and direct injection into the spinal cord.Results: SCH58261, systemically administered (0.01 mg/kg intraperitoneal. 1, 6 and 10 hours after SCI), reduced demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK mitogen-activated protein kinase (MAPK) 24 hours after SCI. Chronic SCH58261 administration, by mini-osmotic pump delivery for 10 days, improved the neurological deficit up to 10 days after SCI. Adenosine A2Areceptors are physiologically expressed in the spinal cord by astrocytes, microglia and oligodendrocytes. Soon after SCI (24 hours), these receptors showed enhanced expression in neurons. Both the A2Aagonist and antagonist, administered intraperitoneally, reduced expression of the A2Areceptor, ruling out the possibility that the neuroprotective effects of the A2Aagonist are due to A2Areceptor desensitization. When the A2Aantagonist and agonist were centrally injected into injured SC, only SCH58261 appeared neuroprotective, while CGS21680 was ineffective.Conclusions: Our results indicate that the A2Aantagonist protects against SCI by acting on centrally located A2Areceptors. It is likely that blockade of A2Areceptors reduces excitotoxicity. In contrast, neuroprotection afforded by the A2Aagonist may be primarily due to peripheral effects.


  • Open Access

    Recessive congenital myotonia resulting from maternal isodisomy of chromosome 7: a case report

    by Cristina Bulli, Pier Antonio Battistella, Marta Bordignon, Placido Bramanti, Giuseppe Novelli, Federica Sangiuolo

    Autosomal dominant (Thomsen) and recessive (Becker) congenital myotonia are two different non dystrophic disorders, due to allelic mutations of the muscle chloride channel gene, located on chromosome 7q35. More than two thirds of the muscle chloride channel gene mutations occur independently in unique families and cause the recessive form of the disease. Becker disease is more common and severe than Thomsen disease. Here, we report on the clinical and molecular data of the first patient with maternal uniparental disomy for chromosome 7 and recessive congenital myotonia. The proband is a 15-year-old male, homozygous for a missense mutation within muscle chloride channel gene, showing few characteristic signs of the Silver Russell Syndrome.